Multiply resistant gram-positive bacteria methicillin-resistant, vancomycin-intermediate and vancomycin-resistant staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Garzoni, C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Infection; MRSA; Staphylococcus aureus; Therapy; Transplantation; VRSA

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ICLAPRIM; LINEZOLID; ORITAVANCIN; TIGECYCLINE;

ARTHRALGIA; BACTEREMIA; BACTERIAL COLONIZATION; ENDOCARDITIS; GRAFT RECIPIENT; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INJECTION SITE REACTION; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER TRANSPLANTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYALGIA; NONHUMAN; OPTIC NERVE DISEASE; ORGAN TRANSPLANTATION; OSTEOMYELITIS; PENICILLIN RESISTANCE; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; ORGAN TRANSPLANTATION; VANCOMYCIN;

EID: 72949105391     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02892.x     Document Type: Review

References (50)

1. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004 32 : 470 485.
2. Rosenthal VD, Maki DG, Mehta A et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008 36 : 627 637.
3. Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008 51 : 291 298.
4. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007 298 : 1763 1771.
5. Navarro MB, Huttner B, Harbarth S. Methicillin-resistant Staphylococcus aureus control in the 21st century: beyond the acute care hospital. Curr Opin Infect Dis 2008 21 : 372 379.
6. Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006 42 : 647 656.
7. Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz LD. Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 2009 30 : 4 8.
8. Adeyemi OA, Qi C, Zembower TR et al. Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation. J Clin Microbiol 2008 46 : 2809 2813.
9. Obed A, Schnitzbauer AA, Bein T, Lehn N, Linde HJ, Schlitt HJ. Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation 2006 81 : 121 124.
10. Chua T, Moore CL, Perri MB et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 2008 46 : 2345 2352.
11. Bert F, Clarissou J, Durand F et al. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol 2003 41 : 5147 5152.
12. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007 44 : 1208 1215.
13. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008 46 : 668 674.
14. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008 46 (Suppl 5 S344 S349.
15. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008 46 (Suppl 5 S350 S359.
16. Asensio A, Guerrero A, Quereda C, Lizan M, Martinez-Ferrer M. Colonization and infection with methicillin-resistant Staphylococcus aureus: Associated factors and eradication. Infect Control Hosp Epidemiol 1996 17 : 20 28.
17. Singh N, Paterson DL, Chang FY et al. Methicillin-resistant Staphylococcus aureus: The other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000 30 : 322 327.
18. Santoro-Lopes G, de Gouvea EF, Monteiro RC et al. Colonization with methicillin-resistant Staphylococcus aureus after liver transplantation. Liver Transpl 2005 11 : 203 209.
19. Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol 2006 27 : 122 126.
20. Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005 5 : 751 762.
21. Bert F, Galdbart JO, Zarrouk V et al. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis 2000 31 : 1295 1299.
22. Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl 2003 9 : 754 759.
23. Russell DL, Flood A, Zaroda TE et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008 8 : 1737 1743.
24. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004 39 : 776 782.
25. Larsen AR, Stegger M, Bocher S, Sorum M, Monnet DL, Skov RL. Emergence and characterization of community associated methicillin-resistant Staphyloccocus aureus infections in Denmark, 1999-2006. J Clin Microbiol 2008.
26. Brown DF, Edwards DI, Hawkey PM et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 2005 56 : 1000 1018.
27. CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. Wayne, PA: CLSI, 2006.
28. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin- resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007 30 : 398 408.
29. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008 14 (Suppl 2 3 9.
30. Chambers HF. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997 10 : 781 791.
31. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009 66 : 82 98.
32. Rybak MJ, Lomaestro BM, Rotscahfer JC et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009 49 : 325 327.
33. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007 45 (Suppl 3 S184 190.
34. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006 58 : 1221 1229.
35. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004 351 : 1645 1654.
36. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008 46 (Suppl 5 S378 S385.
37. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr., Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004 42 : 2398 2402.
38. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006 50 : 1079 1082.
39. Calfee DP, Salgado CD, Classen D et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008 29 (Suppl 1 S62 80.
40. Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006 63 (Suppl 1 S1 44.
41. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003 24 : 362 386.
42. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007 35 (Suppl 2 S165 S193.
43. Kluytmans JA, Mouton JW, VandenBergh MF et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996 17 : 780 785.
44. Bode LGM KA, Wertheim HFL, Bogaers D et al. A randomized trial of admission screening and decolonization of Staphylococcus aureus carriers to prevent nosocomial S. aureus infections. In : Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2008, Washington, DC.
45. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006 57 : 589 608.
46. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003 75 : 194 198.
47. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999 43 : 1412 1416.
48. Gorwitz RJJD, Powers JH, Jernigan JA, and Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at : http://www.cdc.gov/ncidod/dhqp/ar-mrsa-ca.html.
49. Longtin Y, Sudre P, Francois P et al. Community-associated methicillin-resistant Staphylococcus aureus: Risk factors for infection, and long-term follow-up. Clin Microbiol Infect 2009 15 : 552 559.
50. Pittet D, Hugonnet S, Harbarth S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000 356 : 1307 1312.